Awad MM, Leonardi GC, Kravets S, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer 2019;133:96 – 102

Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387(10026):1415 – 26

Burns TF, Borghaei H, Ramalingam SS, et al. Targeting KRAS-mutant non- small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations. J Clin Oncol 2020;38(35):4208 – 18

Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27(10):1667 – 74

Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012;25(3):347 – 69

Drilon A, Cappuzzo F, Ou SI, et al. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol 2017;12(1):15 – 26

Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res 2017;6(5):550 – 9

Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5(8):850 – 9

Garon EB, Heist RS, Seto T, et al. Abstract CT082: Capmatinib in METex14- mutated (mut) advanced non-small cell lung cancer (NSCLC): results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM). Cancer Research 2020;80(16 Supplement):CT082

Griesinger F, Eberhardt W, Nusch A, et al. Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer 2021;152:174 – 84

Guisier F, Dubos-Arvis C, Viñas F, et al. Efficacy and safety of anti–PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J Thorac Oncol 2020;15(4):628 – 36

Guo R, Luo J, Chang J, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 2020;17(9):569 – 87

Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. New England Journal of Medicine 2020;383(14):1328 – 39

Hong L, Zhang J, Heymach JV, et al. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1758835921992976

Kraywinkel K, Schönfeld I. Epidemiologie des nichtkleinzelligen Lungenkarzinoms in Deutschland. Der Onkologe 2018;24(12):946 – 51

Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama 2014;311(19):1998 – 2006

Kron A, Scheffler M, Heydt C, et al. Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy. J Thorac Oncol 2021;16(4):572 – 82

Lee M, Jain P, Wang F, et al. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opin Ther Targets 2021;25(4):249 – 68

Leitlinienprogramm Onkologie. S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 1.0, AWMF-Registernummer: 020/007OL. 2018. http://leitlinienprogramm- onkologie.de/Lungenkarzinom.98.0.html, abgerufen am: 24.11.2021

Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 2019;121(9):725 – 37

Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol 2018;36(24):2532 – 7

Li BT, Smit EF, Goto Y, et al. LBA45 - Primary data from DESTINY-Lung01: a phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2021;32(suppl_5):S1283 – S346

Lu S, Fang J, Li X, et al. Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). J Clin Oncol 2020;38(15_suppl):9519

Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30(8):1321 – 8

Onkopedia. Nicht-kleinzelliges Lungenkarzinom. 2021. https://www. onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht- kleinzellig-nsclc/@@guideline/html/index.html, abgerufen am: 02.11.2021

Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011;3(1 Suppl):S7 – s19

Overbeck TR, Cron DA, Schmitz K, et al. Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res 2020;9(3):603 – 16

Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 2020;383(10):931 – 43

Onkopedia. Nicht-kleinzelliges Lungenkarzinom. 2021. https://www. onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht- kleinzellig-nsclc/@@guideline/html/index.html, abgerufen am: 03.09.2021

Ostermann H, Ukena D. Aktuelle Ergebnisse und Entwicklung des Testver- haltens beim NSCLC seit 2012. Journal Onkologie 07/08 2020

Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 2020;383(10):931 – 43

Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%. J Clin Oncol 2021;39(21):2339 – 49

Reungwetwattana T, Liang Y, Zhu V, et al. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer 2017;103:27 – 37

Rossi G, Jocollé G, Conti A, et al. Detection of ROS1 rearrangement in non- small cell lung cancer: current and future perspectives. Lung Cancer (Auckl) 2017;8:45 – 55

Rote Liste. 2021. www.rote-liste.de, abgerufen am: 24.11.2021

Russo A, Lopes AR, Scilla K, et al. NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC). Precision Cancer Medicine 2020;3

Sabari JK, Leonardi GC, Shu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol 2018;29(10):2085 – 91

Schildhaus HU, Schultheis AM, Rüschoff J, et al. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res 2015;21(4):907 – 15

Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17(8):2081 – 6

Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 2019;19(9):495 – 509

Tan AC, Loh TJ, Kwang XL, et al. Novel therapies for metastatic non-small cell lung cancer with MET exon 14 alterations: a spotlight on capmatinib. Lung Cancer (Auckl) 2021;12:11 – 20

Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res 2016;22(12):3048 – 56

Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - a systematic review and meta-analysis. Lung Cancer 2018;123:76 – 82

WHO. Cancer today - fact sheets lung. 2020. https://gco.iarc.fr/today/data/ factsheets/cancers/15-Lung-fact-sheet.pdf, abgerufen am: 24.11.2021

Wolf J, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study. J Clin Oncol 2021;39(15_suppl):9020

Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon 14–mutated or MET- amplified non–small-cell lung cancer. N Engl J Med 2020;383(10):944 – 57

Wu Y-L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine 2020;383(18):1711 – 23

Xu Z, Li H, Dong Y, et al. Incidence and PD-L1 expression of MET 14 skipping in chinese population: a non-selective NSCLC cohort study using RNA- based sequencing. Onco Targets Ther 2020;13:6245 – 53

Yeung SF, Tong JHM, Law PPW, et al. Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor. J Thorac Oncol 2015;10(9):1292 – 300

Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 2018;17(1):45

Zhao J, Xia Y. Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review. JCO Precision Oncology 2020; 10.1200/ PO.19.00333(4):411 – 25